Oxford Pharmascience Group (OXP)

 

OXP Share PerformanceMore

52 week high3.6065 08/02/17
52 week low1.1210 27/10/17
52 week change -0.5200 (-28.11%)
4 week volume86,066,126 24/10/17

Media for (OXP)

Presenter: Marcelo Bravo
25/01/2017
Presenter: Marcelo Bravo
12/09/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Oxford Pharmascience proposes demerger

Oxford Pharmascience has announced an intention to demerge its entire shareholding in a subsidiary that holds all of its c...

Announcement of demerger

RNS Number: 1138W Oxford Pharmascience Group PLC 10 November 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Defined term...

OXP receives MHRA advice on OXPzero

Oxford Pharmascience has confirmed that the Company has received written advice from the MHRA (UK regulatory au...

MHRA Advice on OXPzeroT Ibuprofen OTC Opportunity

RNS Number: 3946S Oxford Pharmascience Group PLC 02 October 2017 2 October 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") MHRA Advice on OXPzero TM Ibuprofen OTC Opportunity Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, t...

Interim Results

RNS Number: 6364R Oxford Pharmascience Group PLC 25 September 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Interim results for the six months to 30 June 2016 Oxford Pharmascience Group Plc (AIM: OXP) is pleased to announce its unaudited interim results for the six months to 30 June 2017. Recent clinical work confir...

All resolutions passed at AGM of Oxford Pharmascience

Oxford Pharmascience Group has confirmed that all resolutions were passed by shareholders at today's Annual General M...

Result of AGM

RNS Number: 4736I Oxford Pharmascience Group PLC 19 June 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Result of AGM Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, is pleased to announce that at its Annual Ge...

Further Update re: OXPzero Ibuprofen Programmes

RNS Number: 5108H Oxford Pharmascience Group PLC 08 June 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the " Company ") Further Update R egarding OXPzero TM Ibuprofen Programmes Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easie...

Fundamental DataMore

EPS-0.11
Dividend yield0 %

Latest discussion posts More

  • Re: At least 18 months

    That seems logical, I will hold on in the HOPE it passes 2p and take a small profit, if not, leave for 2 or 3 years and most probably have this same conversation again.
    3-Apr-2017
    Hyperproject
  • Re: At least 18 months

    I've bailed after a big hit! The way I read it, they have no product. If they want to release it as planned then they need more trials which could cost millions and also, ...
    2-Apr-2017
    high blood pressure1
  • At least 18 months

    I have committed today at 1.7p, my first investment ever in anything outside the FT250. From my understanding of this sector, I don't expect much movement either up or down for ...
    31-Mar-2017
    Hyperproject

Users' HoldingsMore

Users who hold Oxford Pharmascience Group also hold..
SIRIUS MINERALS18%
LLOYDS GRP.16%
OXFORD BIOMED.14%
ID:ISIN:VGG9828A119414%
GLAXOSMITHKLINE12%

Codes & Symbols

ISINGB00B3LXPB43
SymbolsOXP, LSE:OXP, OXP.L, OXP:LN, LON:OXP, XLON:OXP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account